Bone Biologics Corp · NASDAQ:BBLG
Bone Biologics — Investor Presentation (August 2026)
17 slides from Bone Biologics's investor presentation, August 2026
Slide 1: Regenerative Medicine for Bone
NASDAQ: BBLG Regenerative Medicine for Bone INVESTMENT PRESENTATION / AUGUST 2026
Slide 2: Safe Harbor Statement
S A F E H A R B O R STAT E M E N T This presentation contains “forward-looking” statements, including, without limitation, statements relating to: the future of Bone Biologics; our business strategy and plans; the ongoing development of our product candidates; our plans to commercialize, and the mar
Slide 3: Company Overview
C O M PA N Y OV E R V I E W Bone Biologics is redefining bone regeneration with NELL-1, a proprietary growth factor, proven to increase the quantity and quality of bone in preclinical trials, while displaying a strong safety profile $3B LARGE MARKET $3B spine fusion market, with long-term potential
Slide 4: Orthobiologics Market
ORTHOBIOLOGICS MARKET Fragmented $3B Market Poised for Disruption by Next-Generation Solutions STEM CELLS Large Addressable Market 14% GROWTH FACTORS NON-PROPRIETARY 34% ALLOGRAFT 6% $3B SYNTHETICS Global Bone Graft Substitute 27% Market DBM 19% Sources: Orthopedic Network News NASDAQ:BBLG 4
Slide 5: Hard Healer Fusion Remains a Critical Clinical Unmet Need
BONE BIOLOGIC’S SOLUTION Hard Healer Fusion Remains a Critical Clinical Unmet Need A major challenge in orthopedic surgery is effective bone regeneration – especially in hard healers CHALLENGES WITH rhBMP PROPOSED SOLUTION NELL-1 Rapid, uncontrolled bone growth can cause Rapid, controlled, guided bo
Slide 6: NELL-1 Mechanism of Action
N E L L -1 M E C H A N I S M O F A C T I O N rhBMP Improved Safety From Later Pathway Interaction Mesenchymal Stem Cells • NELL-1 acts later in the pathway Differentiates to bone of bone formation and only grows bone in presence of bone Runx2 (improved safety) • Runx2 protein is known as the Pre-ost
Slide 7: NELL-1 MOA Demonstrates Clinical Viability
P E E R R E V I E W S : N E L L -1 Nell-1 MOA Demonstrates Clinical Viability Over 45 peer-reviewed publications support MOA and its potential for better bone formation Novel Wnt Regulator NEL-Like Molecule-1 Antagonizes Adipogenesis and Augments Osteogenesis Induced by Bone Morphogenetic Protein-2.
Slide 8: Seamless Surgeon Adoption
SEAMLESS SURGEON ADOPTION Surgical Procedure Remains the Same No Change to Protocol with Orthobiologic Prep and Implantation NB-1 rhNELL-1 DBM A vial of NELL-1 and A delivery device will allow NELL-1 + DBM mixture is Demineralized Bone Matrix the surgeon to deliver the then inserted into cage, just
Slide 9: Tolerability & Efficacy
TOLERABILITY & EFFICACY Studies Demonstrate Safety and Effectiveness • Spine fusion effectiveness demonstrated across 3 animal species (rodent, sheep, NHP) • Extensive outcome measures including micro CT, x-ray, histology, and biomechanics • Completed two clinically relevant sheep studies that demon
Slide 10: Clinical Strategy
C L I N I C A L ST R AT E GY A Thoughtful Sequence of Clinical Trials Trial Design Primary Endpoint Secondary Endpoints 30 patients: • 12 @ 2.0 mg/mL • Fusion success rate @ 12- months from radiological • Adverse events • 12 @ 1.5 mg/mL assessment • Surgical measurements • 6 @ local autograft • Chan
Slide 11: NELL-1: Next Opportunities
N E L L -1 : N E X T O P P O R T U N I T I E S Focus on Fusion Provides Differentiated Product in Clinical Need CLINICAL INDICATION DISCOVERY PRECLINICAL PILOT PIVOTAL Spine SPINE Fusion FUSION Trauma TRAUMA Osteoporosis OSTEOPOROSIS NASDAQ:BBLG 11
Slide 12: Expected Milestones & Achievements
EXPECTED MILESTONES & ACHIEVEMENTS Clear Pathway to FDA Approval 12-MOS 32-MOS STABILITY STABILITY PILOT INITIATE STUDY STUDY IP STUDY PIVOTAL FDA EXPANDED EXPANDED ADVANCEMENT 12-MOS DATA STUDY SUBMISSION 2024 2025 2026 2027 2028 2029 ENROLLMENT PILOT SUBMIT PIVOTAL STUDY ENROLL 1ST COMPLETE STUDY
Slide 13: Intellectual Property
INTELLECTUAL PROPERTY Strong IP Barrier Patent No. Title Issued U.S. Patent No. 9,447,155 Isoform NELL-1 peptide 9/20/2016 U.S. Patent No. 9,974,828 Isoform NELL-1 peptide 5/22/2018 U.S. Patent No. 11,000,570 Isoform NELL-1 peptide 5/11/2021 U.S. Patent No. 10,335,458 Pharmaceutical compositions for
Slide 14: Leadership Team
LEADERSHIP TEAM Jeffrey Frelick The board of directors are all President & CEO independent and have executive COO Life Science Enterprises operational experience in life science Med-Tech analyst, Canaccord, ThinkEquity, companies Lazard, Leerink Consultant, Boston Biomedical Consultants Regi
Slide 15: Key Financial Highlights
KEY FINANCIAL HIGHLIGHTS Well-Funded, Low Burn, Runway into 2027 Cash on Hand: $4.0 million (as of June 30, 2026) + net $2.7 raised in July 2026 Cash Runway: Current funds expected to support operations into Q2 2027 Shares Out: 2.8 million Market Cap: $1.8 million (as of August 14, 2026) Debt: None
Slide 16: Investment Summary
INVESTMENT SUMMARY NEAR-TERM $3B MARKET OPPORTUNITY • Global target market in spine fusion • Surgeon concern is hard healers - Fusion rates are low - Longer recovery times lead to poorer outcomes • Longer-term potential the $11B osteoporosis and $8B trauma markets NELL-1 SOLUTION • NELL-1 provides r
Slide 17: Contact
C O N TA C T CORE IR Investor Relations (212) 655-0924 investors@bonebiologics.com bonebiologics.com NASDAQ: BBLG